Kolexia
Wattel Eric Hématologie
Wattel Eric
Hématologie
Hôpital Edouard Herriot
Lyon, France
119 Activités
297 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Syndromes myélodysplasiques Leucémie-lymphome à cellules T de l'adulte Préleucémie Délétion de segment de chromosome Infections à HTLV-I Leucémie myélomonocytaire chronique

Collaborateurs

Voir plus
Fenaux Pierre
Fenaux Pierre
Hôpital Saint-Louis, Paris, France
Vey Norbert
Vey Norbert
Centre Paoli-Calmettes, Marseille, France
Thomas Xavier
Thomas Xavier
Hôpital Lyon Sud, Pierre-Bénite, France
Rauzy Odile
Rauzy Odile
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France

Industries

Voir plus
42 market research
1 collaboration(s)
Dernière en 2020
B3TSI
1 collaboration(s)
Dernière en 2020
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   01 décembre 2022
Prognostic impact of ABCA3 expression in adult and pediatric acute myeloid leukemia: an ALFA-ELAM02 joint study.
Blood advances   06 mai 2022
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.
British journal of haematology   19 avril 2022
Posa-Pk: Pharmacokinetics Variability of Posaconazole (PCZ) and Its Glucuronide Metabolite During Induction and Consolidation Treatments in Patients With Acute Myeloid Leukemia (AML): a Covariate Analysis With the Tablets Formulation and Evaluation of the Potential Risk of Hepatotoxicity
Essai Clinique (Hospices Civils de Lyon)   23 février 2022
GFM-DAC-CMML: A Randomized Phase III Study of Decitabine (DAC) With or Without Hydroxyurea (HY) Versus HY in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia (CMML)
Essai Clinique (Janssen)   17 novembre 2021
EPO-PRETAR: A Randomized Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS With Non RBC Transfusion Dependent Anemia and Without Del 5q
Essai Clinique (Groupe Français des Myélodysplasies)   01 décembre 2020
Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial
Blood   05 novembre 2020
Intragenic recruitment of NF-κB drives splicing modifications upon activation by the oncogene Tax of HTLV-1.
Nature communications   16 juin 2020
Lyon-University Hospital Experience with Gemtuzumab Ozogamicin Therapy in Acute Myeloid Leukemia: a 'Real-Life' Study.
Mediterranean journal of hematology and infectious diseases   01 mai 2020
FP068 SIOP19-0564 Independent Prognostic Impact of TET2 and ABCA3 Transcriptional and Post-Transcriptional Profiles in Pediatric Acute Myeloid Leukemia
Abstracts from the 51st Congress of the International Society of Paediatric Oncology (SIOP) Lyon, France, October 23–26, 2019   30 septembre 2019